➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Moodys
McKesson
Johnson and Johnson
Express Scripts

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Ocriplasmin - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for ocriplasmin
Tradenames:1
Patents:8
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for ocriplasmin
Recent Clinical Trials for ocriplasmin

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Wagner Macula & Retina CenterPhase 2
Katholieke Universiteit LeuvenPhase 1
Universitaire Ziekenhuizen LeuvenPhase 1

See all ocriplasmin clinical trials

Pharmacology for ocriplasmin
Ingredient-typePeptide Hydrolases

Company Disclosures: US Patents for ocriplasmin

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial Thromb-X nv (Leuven, BE) 2020-12-21 RX company
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial ThromboGenics NV (Leuven, BE) 2022-12-06 RX company
Thrombogenics, Inc JETREA ocriplasmin INJECTABLE; INTRAVITREAL 125422 001 2012-10-17   Start Trial ThromboGenics NV (Heverlee, BE) 2022-12-06 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ocriplasmin

These patents were identified by searching patent claims

Supplementary Protection Certificates for ocriplasmin

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-0 Sweden   Start Trial MARKNADSGODKAENNANDE NR.: EU/1/13/819/001, 2013-03-15, MIKROPLASMIN
1232252/01 Switzerland   Start Trial PRODUCT NAME: OCRIPLASMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63053 13.03.2014
C0052 France   Start Trial PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130315
13C/055 Belgium   Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE
2013020,C1581254 Lithuania   Start Trial PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Mallinckrodt
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.